Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

被引：0
|
作者：
Mei-Mei Zheng
Yang-Si Li
Hai-Yan Tu
Hao Sun
Kai Yin
Ben-Yuan Jiang
Jin-Ji Yang
Xu-Chao Zhang
Qing Zhou
Chong-Rui Xu
Zhen Wang
Hua-Jun Chen
De-Xiang Zhou
Yi-Long Wu
机构：
[1] School of Medicine,Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital
[2] South China University of Technology,Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer
[3] Guangdong Academy of Medical Sciences,Department of Neurosurgery, Guangdong Provincial People’s Hospital
[4] Guangdong Provincial People’s Hospital,undefined
[5] Guangdong Academy of Medical Sciences,undefined
[6] Guangdong Academy of Medical Sciences,undefined
来源：
BMC Medicine | / 20卷
关键词：
Cerebrospinal fluid; Leptomeningeal metastases; Osimertinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Sun, Hao
    Yin, Kai
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Xu, Chong-Rui
    Wang, Zhen
    Chen, Hua-Jun
    Zhou, De-Xiang
    Wu, Yi-Long
    BMC MEDICINE, 2022, 20 (01)
  • [2] Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
    Jiang, Tao
    Xu, Xiaobo
    Chen, Xiaojuan
    Ding, Ning
    Hu, Qin
    Zhou, Caicun
    Hu, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2514 - 2517
  • [3] Matched Targeted Therapy by cfDNA of CSF Beyond Leptomeningeal Metastases Progression Upon Osimertinib in EGFR-Mutated NSCLC Patients
    Zheng, M.
    Li, Y.
    Tu, H.
    Sun, H.
    Yin, K.
    Yang, J.
    Zhang, X.
    Zhou, Q.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S877 - S877
  • [4] Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhou, Qing
    Xu, Chong-Rui
    Yang, Xiao-Rong
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 250 - 258
  • [5] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [6] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [7] Osimertinib in EGFR-Mutated Advanced NSCLC
    Revannasiddaiah, Swaroop
    Devadas, Santhosh K.
    Maka, Vinayak V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1864 - 1864
  • [8] Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
    Planchard, D.
    Toffart, A. C.
    Flandin, A-C. Madroszyk
    Wislez, M.
    Martinez, S.
    Monnet, I.
    Hiret, S.
    Gounant, V.
    Metivier, A-C.
    Domblides, C.
    Giroux-Leprieur, E.
    Huchot, E.
    Tomasini, P.
    Mascaux, C.
    Carmier, D.
    Langlais, A.
    Morin, F.
    Westeel, V.
    Cortot, A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [9] The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases
    Han, Huan
    Tang, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
    Li, M.
    Mok, K.
    Chan, L. L.
    Lee, K. W. C.
    Loong, H. H. F.
    Lam, K. C.
    Mok, F.
    Lau, Y. M.
    Chen, O.
    Ng, J.
    Lam, B.
    Chen, A.
    Wong, W.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2023, 34
12345